<code id='51210D42C4'></code><style id='51210D42C4'></style>
    • <acronym id='51210D42C4'></acronym>
      <center id='51210D42C4'><center id='51210D42C4'><tfoot id='51210D42C4'></tfoot></center><abbr id='51210D42C4'><dir id='51210D42C4'><tfoot id='51210D42C4'></tfoot><noframes id='51210D42C4'>

    • <optgroup id='51210D42C4'><strike id='51210D42C4'><sup id='51210D42C4'></sup></strike><code id='51210D42C4'></code></optgroup>
        1. <b id='51210D42C4'><label id='51210D42C4'><select id='51210D42C4'><dt id='51210D42C4'><span id='51210D42C4'></span></dt></select></label></b><u id='51210D42C4'></u>
          <i id='51210D42C4'><strike id='51210D42C4'><tt id='51210D42C4'><pre id='51210D42C4'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:342
          Matts Take Column Illustration
          Molly Ferguson for STAT

          If you’re a drug company executive, you probably feel like you got up on the wrong side of bed.

          On Thursday night, President Biden proposed expanding one of his most popular policies: the Medicare price negotiation process that was put in place as part of the Inflation Reduction Act. “Americans pay more for prescription drugs than anywhere else,” Biden said. “It’s wrong and I’m ending it.”

          advertisement

          Obviously, the drug industry is not going to be happy about new price limitations in the U.S., the biggest market for pharmaceuticals. But, even more than that, Biden’s move emphasizes a painful reality: That pharmaceutical companies remain one of the biggest political targets in the country — despite their key role in addressing the Covid-19 pandemic and their development of wildly effective new weight loss drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more
          Eli Lilly to pay $200M for Beam’s stake in gene
          Eli Lilly to pay $200M for Beam’s stake in gene

          AdobeEliLillysaidTuesdaythatitwillpay$200milliontogene-editingfirmBeamTherapeuticsforBeam’sstakeinVe

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Readout Newsletter: XBI biotech index, Akero Therapeutics

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb